Human Anti-D Immunoglobulin
Description
Human Anti-D Immunoglobulin is a medicine given to prevent the formation of the immune response in women with negative (Rh-negative) blood group who are exposed to the Rh antigen (from a positive blood group fetus) at the time of planned abortion or miscarriage (up to 12 weeks’ gestation). It also suppresses the stimulation of active immunity by Rh-positive fetal blood cells that may enter the maternal circulation at the time of delivery. It is also used for treating Idiopathic thrombocytopenic purpura in Rh-positive patients.
QUICK LINKS:
Side effects
Major & minor side effects for Human Anti-D Immunoglobulin
- Fever and chills
- Decreased blood pressure
- Nausea and Vomiting
- Headache
- Increased blood bilirubin
- Injection site reations (pain,swelling)
- Dizziness
- Back pain
- Fast heartbeat
Uses of Human Anti-D Immunoglobulin
What is it prescribed for?
- Incompatible Pregnancy
- Abortion
- Incompatible transfusion
- Idiopathic thrombocytopenic purpura
Read More
Concerns
Commonly asked questions
- Onset of actionThe peak effect of this medicine can be observed within 5-10 days of intramuscular administration and that of 2 hours with intravenous administration.
- Duration of effectThe amount of time for which this medicine remains effective is subject to vary based on the individual, strength, and form of administration.
- Safe with alcohol?Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
- Is it habit forming?No habit-forming tendencies were reported.
- Usage in pregnancy?This medicine is given for incompatible pregnancy, that is when an Rh-negative women get pregnant with an Rh-positive fetus. But for other indications, this medicine is not recommended for use in pregnant women unless absolutely necessary and the potential benefits outweigh the risks involved. Your doctor will determine the best course of treatment after assessing the clinical condition.
- Usage while breast-feeding?This medicine is not recommended for use in breastfeeding women unless necessary. The risks and benefits should be discussed with the doctor before receiving this medicine. However, immunoglobulins are normal components of breast milk and no undesired effects are expected. Talk to your doctor before breastfeeding.
Allergy
This medicine is not recommended for use in patients with a known allergy to Human Anti-D immunoglobulin or human immunoglobulins or any other inactive ingredient present along with it.
Thrombocytopenia
The intramuscular route of this medicine is contraindicated in persons with severe thrombocytopenia or other disorders of hemostasis and intravenous form in RhD-negative patients, splenectomized individuals, who are at risk/with hemolysis due to the increased risk of worsening of the patient's condition.
Warnings for special population
Pregnancy
This medicine is given for incompatible pregnancy, that is when an Rh-negative women get pregnant with an Rh-positive fetus. But for other indications, this medicine is not recommended for use in pregnant women unless absolutely necessary and the potential benefits outweigh the risks involved. Your doctor will determine the best course of treatment after assessing the clinical condition.
Breast-feeding
This medicine is not recommended for use in breastfeeding women unless necessary. The risks and benefits should be discussed with the doctor before receiving this medicine. However, immunoglobulins are normal components of breast milk and no undesired effects are expected. Talk to your doctor before breastfeeding.
General warnings
Severe allergic reactions
Severe allergic reactions may occur with this medicine, specifically contraindicated in patients with a previous anaphylactic or severe systemic reaction to an immune globulin. Precautions for immediate treatment should be available during use. If symptoms of allergic reactions occur, discontinue immediately and initiate appropriate treatment.
Obesity
Intramuscular administration of this medicine in patients with a body mass index (BMI) ≥ 30 may be associated with an increased risk of lack of effect. So, in patients with a BMI ≥30, intravenous administration should be considered.
Hemolytic reactions
Patients who received very large doses of anti-D immunoglobulin for treating the incompatible transfusion should be monitored clinically and by biological parameters due to the increased risk of hemolytic reaction.
Administration
This medicine is contraindicated for administration in neonates and the intramuscular route is not recommended for treating the idiopathic thrombocytopenic purpura due to the increased risk of worsening of the patient's condition.
IgA deficiency
Certain formulations of this medicine should be used with caution in patients with selective IgA deficiency, who can develop IgA antibodies due to the increased risk of severe anaphylactic reactions.
Missed Dose
Since this medicine is administered by a qualified healthcare professional in the clinical or hospital setting, the likelihood of a missed dose is very low. If you miss an appointment for a scheduled dose of this medicine, contact your doctor immediately for further instructions.
Overdose
Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol
Description
Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Instructions
Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine
Live vaccines
Phenytoin
Gentamicin
Mefenamic acid
Diclofenac
Flurbiprofen
Disease interactions
Anemia
The use of this medicine is contraindicated in patients with autoimmune hemolytic anemia, with preexisting hemolysis or at high risk for hemolysis. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.
Diabetes Mellitus
This medicine should be used with caution in patients with diabetes mellitus since it may show false high blood glucose results. Patients are advised to use only test systems that are glucose-specific to test or monitor blood glucose levels in patients receiving this medicine.
Kidney Disease
This medicine should be used with caution in patients suffering from kidney dysfunction due to the increased risk of severe side effects. Appropriate dose adjustments and frequent monitoring of kidney function tests are advised in such cases. Replacement with a suitable alternative may be required in some cases based on the clinical condition.
Thromboembolism
This medicine should be used with caution in patients with a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, coagulation disorders, prolonged periods of immobilization, etc due to increased risk of thromboembolism. Close monitoring, dose modification and replacement with a suitable alternative may be required based on the clinical condition.
Food interactions
Information not available.
Lab interactions
Information not available.
This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor. Inform the doctor if you have a known allergy to this medicine. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine. Your dose regimen and frequency of administration is likely to vary based on the condition being treated. Consult your doctor immediately if you develop any adverse reactions.
Miscelleneous
How it works
This medicine works by preventing the antibody response by destroying the foreign blood cells (from the fetus) and by clearing it from the maternal circulation before the recognition by the immune system.
Legal Status
Classification
Category
Immune globulins
Schedule
Schedule H
[Internet]. Dailymed.nlm.nih.gov. 2018 [cited 27 September 2018]. Available from:
[Internet]. Medicines.org.uk. 2018 [cited 27 September 2018]. Available from:
[Internet]. Ebs.tga.gov.au. 2018 [cited 27 September 2018]. Available from:
[Internet]. Drugbank.ca. 2018 [cited 27 September 2018]. Available from:
Information on this page was last updated on 9 Jan 2019
Disclaimer
We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.